A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: Critical determinants for successful correction

Blood

Volumn 114, Issue 6, 2009, Pages 1174-1185

  Perumbeti, Ajay ^a   Higashimoto, Tomoyasu ^a   Urbinati, Fabrizia ^a   Franco, Robert ^b   Meiselman, Herbert J ^c   Witte, David ^b   Malik, Punam ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; GAMMA GLOBIN; HEMOGLOBIN F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GLOBIN GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SICKLE CELL ANEMIA; ANIMAL; BIOSYNTHESIS; BLOOD; DISEASE MODEL; ERYTHROCYTE DISORDER; GENETICS; HUMAN; MEAN CORPUSCULAR VOLUME; METABOLISM; MOUSE MUTANT; REGULATORY SEQUENCE;

ANEMIA, SICKLE CELL; ANIMALS; DISEASE MODELS, ANIMAL; ERYTHROCYTE INDICES; ERYTHROCYTES, ABNORMAL; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, SCID; REGULATORY ELEMENTS, TRANSCRIPTIONAL;

EID: 69849094491     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-201863     Document Type: Article

References (48)

1. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858-863. (Pubitemid 44682188)
2. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644. (Pubitemid 124005049)
3. Davis H, Schoendorf KC, Gergen PJ, Moore RM Jr. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87(8):1317-1322.
4. World Health Organization. Sickle-Cell Anaemia. Fifty-Ninth World Health Assembly, Provisional Agenda Item 11.4. 2006;A59:1. http://www.who.int/gb/ebwha/ pdf-files/WHA59/A59-9-en.pdf. Accessed June 13, 2006.
5. Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996;2(2):100-104. (Pubitemid 126488201)
6. Fitzhugh CD, Perl S, Hsieh MM. Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD) [letter]. Blood. 2008;111(3):1742-1743; author reply 1744. (Pubitemid 351213472)
7. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756. (Pubitemid 47523201)
8. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368-2371. (Pubitemid 33140563)
9. Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood. 2003;102(13):4312-4319.
10. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood. 2004;104(12):3445-3453. (Pubitemid 39564412)
11. Moreau-Gaudry F, Xia P, Jiang G, et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood. 2001;98(9):2664-2672.
12. Rubin JE, Pasceri P, Wu X, Leboulch P, Ellis J. Locus control region activity by 5′HS3 requires a functional interaction with beta-globin gene regulatory elements: expression of novel beta/gamma-globin hybrid transgenes. Blood. 2000;95(10):3242-3249. (Pubitemid 30321180)
13. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther. 2007;15(10):1863-1871. (Pubitemid 47434195)
14. Pászty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878. (Pubitemid 27467927)
15. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006;107(4):1651-1658.
16. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003;29(5):435-450.
17. Iannone R, Luznik L, Engstrom LW, et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood. 2001;97(12):3960-3965.
18. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9(8):519-528. (Pubitemid 38351796)
19. Hardeman MR, Ince C. Clinical potential of in vitro measured red cell deformability, a myth? Clin Hemorheol Microcirc. 1999;21(3-4):277-284. (Pubitemid 30130904)
20. Franco RS, Lohmann J, Silberstein EB, et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest. 1998;101(12):2730-2740. (Pubitemid 28294582)
21. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther. 2009;17(2):245-252.
22. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998;4(7):775-780. (Pubitemid 28331017)
23. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-2413. (Pubitemid 34734219)
24. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
25. Noronha PA, Vida LN, Park CL, Honig GR. Hemoglobin-specific antibody in a multiply transfused patient with sickle cell disease. Blood. 1997;89(6):2155-2158. (Pubitemid 27132133)
26. Samakoglu S, Lisowski L, Budak-Alpdogan T, et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol. 2006;24(1):89-94. (Pubitemid 43083171)
27. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood. 1994;84(9):3189-3197. (Pubitemid 24328114)
28. Blouin MJ, Beauchemin H, Wright A, et al. Genetic correction of sickle cell disease: insights using transgenic mouse models. Nat Med. 2000;6(2):177-182. (Pubitemid 30082362)
29. Fabry ME, Suzuka SM, Weinberg RS, et al. Second generation knockout sickle mice: the effect of HbF. Blood. 2001;97(2):410-418.
30. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood. 2003;101(6):2175- 2183. (Pubitemid 36302055)
31. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96(7):2379-2384. (Pubitemid 30745258)
32. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood. 1987;69(1):109-116. (Pubitemid 17007083)
33. Maier-Redelsperger M, de Montalembert M, Flahault A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients: The French Study Group on Sickle Cell Disease. Blood. 1998;91(12):4472-4479.
34. Marcus SJ, Ware RE. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention. J Pediatr Hematol Oncol. 1999;21(5):407-411.
35. Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood. 1994;84(9):3182-3188. (Pubitemid 24328113)
36. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651. (Pubitemid 37430269)
37. Kean LS, Manci EA, Perry J, et al. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood. 2003;102(13):4582- 4593. (Pubitemid 37494128)
38. Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665-673. (Pubitemid 34055819)
39. Cavazzana-Calvo M, Cartier N, Abina SH-B, et al. Hematopoietic stem cell gene therapy trial with lentiviral vector in X-linked adrenoleukodystrophy. Blood (ASH Annual Meeting Abstracts). 2008;(suppl)112. Abstract 821.
40. Benhamida S, Pflumio F, Dubart-Kupperschmitt A, et al. Transduced CD34+ cells from adreno-leukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther. 2003;7(3):317-324. (Pubitemid 36503855)
41. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit antithymocyte globulin. Bone Marrow Transplant. 2005;35(2):171-177. (Pubitemid 40185933)
42. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med. 2001;344(1):68. (Pubitemid 32064856)
43. Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002;99(5):1840-1849.
44. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14(11):1270-1278.
45. Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood. 2008;111(4):1866-1875.
46. Ryu BY, Persons DA, Evans-Galea MV, Gray JT, Nienhuis AW. A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis. 2007;39(3):221-228.
47. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687-696. (Pubitemid 43882120)
48. von Kalle C, Baum C, Williams DA. Lenti in red: progress in gene therapy for human hemoglobinopathies. J Clin Invest. 2004;114(7):889-891. (Pubitemid 39578714)